P/B
1,8
Olema Pharmaceuticals
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
$765.6M
Market Cap • 9/25/2026
2006
(20 years)
Founded
2020
(6 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
4,5
EPS
—
Market Cap
Market Cap
765,6M
EV
308,2M
EV/Revenue
0
EV/EBITDA
-1,4
EV/EBIT
-1,4
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-34%
Total Yield
-34%
Payout
0%
Retained Earnings
-713,8M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
—
% PPE
3,4%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Op. Income 5Y
34,6%
CAGR Net Income 5Y
32,7%
CAGR EPS 5Y
-15,8%
CAGR OCF 5Y
35,1%
Leverage
N.D./EBITDA
2,1
Debt/Equity
0%
Current Ratio
8,9
Quick Ratio
8,7
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!